Effect of baseline rheumatoid factor (RF) levels on DAS28-response to standard DMARD-combination treatment in patients with rheumatoid arthritis (RA)

Anand N. Malaviya, John B. Collings, Ashima Makol, Prashant Kaushik

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Rheumatoid factor (RF) positivity has been associated with an unfavourable outcome in rheumatoid arthritis (RA). Our study aimed to find a baseline RF cut-off level that would determine the response to standard disease modifying anti-rheumatic drug (DMARD) combination treatment. Patients and methods: We studied 233 seropositive (RF levels ≥20 IU/mL at presentation) RA patients over a period of up to 5 years. Disease activity was assessed at each patient-encounter using disease activity score on 28 joints (DAS28). Treatment consisted of weekly methotrexate, daily hydroxychloroquine and low dose oral methlyprednisolone as an adjunct. Sulfasalazine or leflunomide were added to the ongoing regimen if satisfactory response was not achieved by 3 months of treatment. Individual response of patients to treatment was graded using the following DAS28 cut-off values: <3 as low disease activity (satisfactory response), ≥3 as moderate and ≥5.1 as high (unsatisfactory response). Results: By analyzing all possible 2 x 2 contingency tables based on the different values of RF in the data set, using Fisher's exact test of association between RF levels and DAS28 values, a cut-off level for RF of 70 IU/mL gave the optimal discrimination between 'low' versus 'moderate or high' disease activity in the follow-up. Conclusion: A baseline RF cut-off value of 70 IU/mL appears to predict a 'satisfactory' versus 'unsatisfactory' response to standard DMARD-combination therapy in RA over time.

Original languageEnglish (US)
Pages (from-to)51-55
Number of pages5
JournalIndian Journal of Rheumatology
Volume4
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Antirheumatic Agents
Rheumatoid Factor
Drug Combinations
Rheumatoid Arthritis
Joints
leflunomide
Therapeutics
Hydroxychloroquine
Sulfasalazine
Methotrexate
Drug Therapy

Keywords

  • Disease-modifying anti-rheumatic drugs (DMARDS)
  • Drug response
  • Predictive value
  • Rheumatoid arthritis
  • Rheumatoid factor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Effect of baseline rheumatoid factor (RF) levels on DAS28-response to standard DMARD-combination treatment in patients with rheumatoid arthritis (RA). / Malaviya, Anand N.; Collings, John B.; Makol, Ashima; Kaushik, Prashant.

In: Indian Journal of Rheumatology, Vol. 4, No. 2, 2009, p. 51-55.

Research output: Contribution to journalArticle

@article{84b555d6c44f411ba2bd97b5e5a0569c,
title = "Effect of baseline rheumatoid factor (RF) levels on DAS28-response to standard DMARD-combination treatment in patients with rheumatoid arthritis (RA)",
abstract = "Objective: Rheumatoid factor (RF) positivity has been associated with an unfavourable outcome in rheumatoid arthritis (RA). Our study aimed to find a baseline RF cut-off level that would determine the response to standard disease modifying anti-rheumatic drug (DMARD) combination treatment. Patients and methods: We studied 233 seropositive (RF levels ≥20 IU/mL at presentation) RA patients over a period of up to 5 years. Disease activity was assessed at each patient-encounter using disease activity score on 28 joints (DAS28). Treatment consisted of weekly methotrexate, daily hydroxychloroquine and low dose oral methlyprednisolone as an adjunct. Sulfasalazine or leflunomide were added to the ongoing regimen if satisfactory response was not achieved by 3 months of treatment. Individual response of patients to treatment was graded using the following DAS28 cut-off values: <3 as low disease activity (satisfactory response), ≥3 as moderate and ≥5.1 as high (unsatisfactory response). Results: By analyzing all possible 2 x 2 contingency tables based on the different values of RF in the data set, using Fisher's exact test of association between RF levels and DAS28 values, a cut-off level for RF of 70 IU/mL gave the optimal discrimination between 'low' versus 'moderate or high' disease activity in the follow-up. Conclusion: A baseline RF cut-off value of 70 IU/mL appears to predict a 'satisfactory' versus 'unsatisfactory' response to standard DMARD-combination therapy in RA over time.",
keywords = "Disease-modifying anti-rheumatic drugs (DMARDS), Drug response, Predictive value, Rheumatoid arthritis, Rheumatoid factor",
author = "Malaviya, {Anand N.} and Collings, {John B.} and Ashima Makol and Prashant Kaushik",
year = "2009",
doi = "10.1016/S0973-3698(10)60174-4",
language = "English (US)",
volume = "4",
pages = "51--55",
journal = "Indian Journal of Rheumatology",
issn = "0973-3698",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of baseline rheumatoid factor (RF) levels on DAS28-response to standard DMARD-combination treatment in patients with rheumatoid arthritis (RA)

AU - Malaviya, Anand N.

AU - Collings, John B.

AU - Makol, Ashima

AU - Kaushik, Prashant

PY - 2009

Y1 - 2009

N2 - Objective: Rheumatoid factor (RF) positivity has been associated with an unfavourable outcome in rheumatoid arthritis (RA). Our study aimed to find a baseline RF cut-off level that would determine the response to standard disease modifying anti-rheumatic drug (DMARD) combination treatment. Patients and methods: We studied 233 seropositive (RF levels ≥20 IU/mL at presentation) RA patients over a period of up to 5 years. Disease activity was assessed at each patient-encounter using disease activity score on 28 joints (DAS28). Treatment consisted of weekly methotrexate, daily hydroxychloroquine and low dose oral methlyprednisolone as an adjunct. Sulfasalazine or leflunomide were added to the ongoing regimen if satisfactory response was not achieved by 3 months of treatment. Individual response of patients to treatment was graded using the following DAS28 cut-off values: <3 as low disease activity (satisfactory response), ≥3 as moderate and ≥5.1 as high (unsatisfactory response). Results: By analyzing all possible 2 x 2 contingency tables based on the different values of RF in the data set, using Fisher's exact test of association between RF levels and DAS28 values, a cut-off level for RF of 70 IU/mL gave the optimal discrimination between 'low' versus 'moderate or high' disease activity in the follow-up. Conclusion: A baseline RF cut-off value of 70 IU/mL appears to predict a 'satisfactory' versus 'unsatisfactory' response to standard DMARD-combination therapy in RA over time.

AB - Objective: Rheumatoid factor (RF) positivity has been associated with an unfavourable outcome in rheumatoid arthritis (RA). Our study aimed to find a baseline RF cut-off level that would determine the response to standard disease modifying anti-rheumatic drug (DMARD) combination treatment. Patients and methods: We studied 233 seropositive (RF levels ≥20 IU/mL at presentation) RA patients over a period of up to 5 years. Disease activity was assessed at each patient-encounter using disease activity score on 28 joints (DAS28). Treatment consisted of weekly methotrexate, daily hydroxychloroquine and low dose oral methlyprednisolone as an adjunct. Sulfasalazine or leflunomide were added to the ongoing regimen if satisfactory response was not achieved by 3 months of treatment. Individual response of patients to treatment was graded using the following DAS28 cut-off values: <3 as low disease activity (satisfactory response), ≥3 as moderate and ≥5.1 as high (unsatisfactory response). Results: By analyzing all possible 2 x 2 contingency tables based on the different values of RF in the data set, using Fisher's exact test of association between RF levels and DAS28 values, a cut-off level for RF of 70 IU/mL gave the optimal discrimination between 'low' versus 'moderate or high' disease activity in the follow-up. Conclusion: A baseline RF cut-off value of 70 IU/mL appears to predict a 'satisfactory' versus 'unsatisfactory' response to standard DMARD-combination therapy in RA over time.

KW - Disease-modifying anti-rheumatic drugs (DMARDS)

KW - Drug response

KW - Predictive value

KW - Rheumatoid arthritis

KW - Rheumatoid factor

UR - http://www.scopus.com/inward/record.url?scp=84992236264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992236264&partnerID=8YFLogxK

U2 - 10.1016/S0973-3698(10)60174-4

DO - 10.1016/S0973-3698(10)60174-4

M3 - Article

AN - SCOPUS:84992236264

VL - 4

SP - 51

EP - 55

JO - Indian Journal of Rheumatology

JF - Indian Journal of Rheumatology

SN - 0973-3698

IS - 2

ER -